Manumycin A
Based on 2 publication(s) in Google Scholar
Manumycin A is a polyketide antibiotic and an inhibitor of thioredoxin reductase 1 (TrxR-1). Manumycin A can inhibit the growth of breast cancer cells and exert its anti-tumor activity through LC3. Manumycin A can downregulate the release of pro-inflammatory cytokines in human monocytes stimulated by TNF α, and has potential anti-inflammatory activity. Manumycin A can inhibit the Ras/Raf/ERK1/2 signaling and hnRNP H1 in castration resistant prostate cancer cells to suppress exosome biogenesis and secretion.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 98.30%
- CAS No.: 52665-74-4
- 화학식: C31H38N2O7
- 분자량:550.64
-
보관:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Manumycin A
MoreAll Antibiotic Isoforms
MoreAll Phospholipase Isoforms
More
Biological Activity
Manumycin A (0.25-5 μM, 24 h) downregulates the release of pro-inflammatory cytokines in human monocytes stimulated by TNF α, thus possessing potential anti-inflammatory properties[1]. Manumycin A (0-25 μM, 72 h) can enhance its inhibitory effect on lung cancer cells after inhibiting HSF1 mediated heat shock response (HSR)[2]. Manumycin A (5 μM, 72 h) inhibits the growth of triple negative breast cancer cells through LC3 mediated cytoplasmic vacuolation death[3]. Manumycin A (250 nM, 48 h) inhibits exosome biogenesis and secretion by targeting Ras/Raf/ERK1/2 signaling and hnRNP H1 in castration resistant prostate cancer cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human monocytic leukemia cells THP-1
-
Concentration:0.25-5 μM
-
Incubation Time:24 h
-
Result:Inhibited the production and release of IL-1 β, IL-6, and IL-8.
-
Cell Line:Lung cancer cell lines NCI-H1299, NCI-H23, A549
-
Concentration:0-25 μM
-
Incubation Time:72 h
-
Result:Enhanced growth inhibition of NSCLC cells after inhibiting HSPA1 expression.
-
Cell Line:Triple-negative breast cancer (TNBC) cells (MDA-MB-231, HCC1937, BT-20)
-
Concentration:5 μM
-
Incubation Time:72 h
-
Result:Inhibited the cell viability of different TNBC cell lines.
-
Cell Line:C4-2B cell
-
Concentration:250 nM
-
Incubation Time:48 h
-
Result:Reduced protein levels of extracellular vesicle biogenic markers Alix, Hrs, and Rab27a.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female nude mice with breast cancer transplanted with MDAMB-231 cells[3].
-
Dosage:5 mg/kg
-
Administration:Intraperitoneal injection (i.p.); Once every two days; 2 weeks
-
Result:Inhibited tumor growth and increased levels of ER stress markers such as Bip, CHOP, LC3, and p62 proteins, as well as higher molecular weight ubiquitinated proteins.
-
Animal Model:HSALR transgenic mice[5].
-
Dosage:3 μg
-
Administration:Intramuscular injection (i.m.); once
-
Result:Reduced the content of Clcn1 exon 7A introns.
Chemical Information
-
CAS No. 52665-74-4
-
Appearance Solid
-
분자량 550.64
-
화학식 C31H38N2O7
-
Color Yellow to orange
-
SMILES
CCCC[C@@H](C)/C=C(C)/C=C(C)/C(NC1=C[C@](/C=C/C=C/C=C/C(NC2=C(O)CCC2=O)=O)(O)[C@]3([H])O[C@]3([H])C1=O)=O
-
Structure Classification
-
Initial Source
new Streptomyces strain
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
-
Inflamm Res
Lipopolysaccharide (LPS) induces sclerostin secretion by extracellular vesicle via TLR4/miR-92a-3p/PTEN/NF-κB signalling pathway in murine macrophage. [Abstract]2025 Jan 25;74(1):27. PMID: 39862242
용액&용해도
DMSO : 50 mg/mL (90.80 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (2.27 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (280 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Cecrdlova E, et al. Manumycin A downregulates release of proinflammatory cytokines from TNF alpha stimulated human monocytes. Immunol Lett. 2016 Jan;169:8-14. [Content Brief]
[2]. Sojka DR, et al. Inhibition of the Heat Shock Protein A (HSPA) Family Potentiates the Anticancer Effects of Manumycin A. Cells. 2021 Jun 7;10(6):1418. [Content Brief]
[4]. Datta A, et al. Manumycin A suppresses exosome biogenesis and secretion via targeted inhibition of Ras/Raf/ERK1/2 signaling and hnRNP H1 in castration-resistant prostate cancer cells. Cancer Lett. 2017 Nov 1;408:73-81. [Content Brief]
[5]. Oana K, et al. Manumycin A corrects aberrant splicing of Clcn1 in myotonic dystrophy type 1 (DM1) mice. Sci Rep. 2013;3:2142. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8161 mL | 9.0803 mL | 18.1607 mL | 45.4017 mL |
| 5 mM | 0.3632 mL | 1.8161 mL | 3.6321 mL | 9.0803 mL | |
| 10 mM | 0.1816 mL | 0.9080 mL | 1.8161 mL | 4.5402 mL | |
| 15 mM | 0.1211 mL | 0.6054 mL | 1.2107 mL | 3.0268 mL | |
| 20 mM | 0.0908 mL | 0.4540 mL | 0.9080 mL | 2.2701 mL | |
| 25 mM | 0.0726 mL | 0.3632 mL | 0.7264 mL | 1.8161 mL | |
| 30 mM | 0.0605 mL | 0.3027 mL | 0.6054 mL | 1.5134 mL | |
| 40 mM | 0.0454 mL | 0.2270 mL | 0.4540 mL | 1.1350 mL | |
| 50 mM | 0.0363 mL | 0.1816 mL | 0.3632 mL | 0.9080 mL | |
| 60 mM | 0.0303 mL | 0.1513 mL | 0.3027 mL | 0.7567 mL | |
| 80 mM | 0.0227 mL | 0.1135 mL | 0.2270 mL | 0.5675 mL |
Powered by Bioz